Effects of Curcumin on the treatment of oral lichen planus symptoms: a systematic review and meta-analysis study.

BACKGROUND AND OBJECTIVES: Oral lichen planus (OLP) is a relatively common chronic T-cell-mediated disease that can cause significant pain, particularly in its erosive or ulcerative forms. This study aimed to examine the therapeutic impact of curcumin on symptoms of OLP. MATERIALS AND METHODS: This meta-analysis was performed according to the PRISMA guidelines. All related English documents indexed in electronic databases (including PubMed, Web of Science, Scopus, Embase, Wiley, Cochrane, and ProQuest databases [updated to August 15, 2023]) were retrieved. Data were double-extracted into a predefined worksheet, and quality analysis was performed using the Joanna Briggs Institute (JBI) scale. We carried out meta-analyses, and the random effects model was used to estimate the differences in erythema, lesion size, and pain between the curcumin control groups. RESULTS: The search identified 289 studies, of which 10 were found to meet the inclusion criteria. The overall findings of the meta-analysis revealed that curcumin did not have a significant effect on erythema of OLP (standardized mean difference [SMD] = -0.14; 95% CI, -0.68 to 0.40; P = 0.61; I2 = 57.50%), lesion size of OLP (SMD = -0.15; 95% CI, -0.45 to 0.15; P = 0.33; I2 = 28.42%), and pain of OLP (SMD = -0.38; 95% CI, -0.97 to 0.22; P = 0.22; I2 = 86.60%). However, subgroup analysis based on treatment duration indicated that 2-week treatment duration was significantly associated with a reduction in OLP pain (n = 3; SMD = -1.21; 95% CI, -2.19 to -0.23; P = 0.01). CONCLUSIONS: Curcumin had no significant effect on erythema, lesion size, and pain of OLP compared to the control groups. However, subgroup analysis revealed that curcumin was more effective in reducing pain in non-randomized trials and in trials with a treatment duration of 2 weeks.

Efeitos adversos locorregionais da terapêutica oncológica em mulheres com câncer de mama avançado: revisão integrativa / Efectos adversos locorregionales de la terapia oncológica en mujeres con cáncer de mama avanzado: una revisión integradora / Locoregional adverse effects of cancer therapy in women with advanced breast cancer: an integrative review

RESUMO Objetivo: identificar os efeitos adversos locorregionais da administração da terapêutica oncológica endovenosa em mulheres com câncer de mama avançado. Metodo: revisão integrativa da literatura, que utilizou as bases de dados PubMed/MEDLINE, CINAHL, LILACS e EMBASE, sem recorte temporal, além de busca reversa dos artigos selecionados, atualizada até maio de 2022 A população contemplou mulheres com câncer de mama avançado submetidas à intervenção com terapêutica oncológica endovenosa com quimioterapia ou hormonioterapia ou anticorpo monoclonal, e o desfecho avaliou efeitos adversos locorregionais Resultados: identificaram-se 2.789 estudos, e a amostra final foi composta por 8 ensaios clínicos e 1 estudo observacional retrospectivo, sendo todos estudos internacionais e publicados no período de 1986 a 2018. Predominantemente, as pacientes tinham câncer de mama em estádio IV, idade de 50 anos ou mais e múltiplas metástases. Os efeitos adversos locorregionais foram: flebite, ulceração e/ou necrose, dor, eritema e reação no local da injeção não especificada. Os estudos não trazem detalhamento do tipo de cateter venoso, osmolaridade dos fármacos e cuidados preventivos para diminuição desses efeitos adversos. Conclusão: as evidências desses artigos mostraram que os efeitos adversos locorregionais estão presentes em estudos de eficácia dos fármacos oncológicos em mulheres com câncer de mama avançado. No entanto, destaca-se que a segurança da administração dos fármacos oncológicos não se apresenta elucidada nessa revisão, indicando necessidade de estudos de acompanhamento dos efeitos adversos.

RESUMEN Objetivo: identificación de los efectos adversos locorregionales de la administración de la terapia oncológica intravenosa en mujeres con cáncer de mama avanzado. Método: revisión bibliográfica integradora, que utilizó las bases de datos PubMed/MEDLINE, CINAHL, LILACS y EMBASE, sin corte de tiempo, además de una búsqueda inversa de los artículos seleccionados, actualizada hasta mayo de 2022 La población incluyó mujeres con cáncer de mama avanzado, sometidas a intervención con terapia oncológica endovenosa con quimioterapia u hormonoterapia o anticuerpo monoclonal y el resultado evaluó los efectos adversos locorregionales Resultados: se identificaron 2.789 estudios y la muestra final se compuso de ocho ensayos clínicos, un estudio observacional retrospectivo, todos estudios internacionales, publicados desde 1986 hasta 2018. Predominantemente, las pacientes tenían cáncer de mama en estadio IV, edad de 50 años o más y metástasis múltiples. Los efectos adversos locorregionales fueron flebitis, ulceración y/o necrosis, dolor, eritema y reacción en el lugar de la inyección no especificada. Los estudios no detallan el tipo de catéter venoso, la osmolaridad de los fármacos y los cuidados preventivos para reducir estos efectos adversos. Conclusión: las pruebas de estos artículos mostraron que los efectos adversos locorregionales están presentes en los estudios de eficacia de los fármacos oncológicos en mujeres con cáncer de mama avanzado. Sin embargo, cabe destacar que la seguridad de la administración de los fármacos contra el cáncer no se dilucida en esta revisión, lo que indica la necesidad de realizar estudios de seguimiento sobre los efectos adversos.

ABSTRACT Objective: to identify the locoregional adverse effects of administering intravenous oncologic therapy in women with advanced breast cancer. Method: this was an integrative literature review using the PubMed/MEDLINE, CINAHL, LILACS, and EMBASE databases, without a time cut, in addition to a reverse search of the selected articles updated until May 2022. The population included women with advanced breast cancer undergoing intervention with intravenous oncologic therapy with chemotherapy, hormone therapy, or monoclonal antibody, and the outcome assessed locoregional adverse effects. Results: 2,789 studies were identified, and the final sample consisted of 8 clinical trials and 1 retrospective observational study, all of which were international studies published from 1986 to 2018. Predominantly, patients with stage IV breast cancer, were aged 50 years or older, and had multiple metastases. Locoregional adverse effects were phlebitis, ulceration and/or necrosis, pain, erythema, and unspecified injection site reaction. The studies did not detail the type of venous catheter, the osmolarity of the drugs, and preventive care to reduce these adverse effects. Conclusion: the evidence from these articles showed that locoregional adverse effects are present in efficacy research of oncologic drugs in women with advanced breast cancer. Nonetheless, the safety of administering cancer drugs is not elucidated in this review, indicating the need for follow-up studies of adverse effects.

Linfedema facial secundario a enfermedad de morbus Morbihan / Facial lymphedema due to Morbihan disease

El linfedema facial es una patología poco frecuente y suele ser secundario al tratamiento de tumores de cabeza y cuello. La enfermedad de Morbihan es una rara entidad que se caracteriza por la aparición de eritema y edema en el tercio medio y superior de la cara, de consistencia habitualmente dura. Su diagnóstico, valoración y tratamiento es muy complicado. Presentamos el caso de un paciente derivado a consultas de Rehabilitación por edema facial duro y dificultad para apertura ocular. La intervención rehabilitadora junto con el drenaje linfático manual consiguió una mejoría del edema, de la dureza y de la dificultad de la visión, valorado mediante la escala visual analógica. El linfedema facial es una entidad poco frecuente, de difícil valoración y con estudios escasos acerca de su tratamiento. El drenaje linfático manual puede ser una ayuda para mejorar el edema y en consecuencia la calidad de vida de estos pacientes (AU)

Facial lymphedema is an infrequent condition that is often caused by treatment for head and neck cancer. Morbihan disease is a rare entity characterised by the development of erythema and solid oedema in the middle and upper third of the face. The evaluation, diagnosis and treatment of this condition are hugely complicated. We report the case of a male patient who was referred to the rehabilitation department for hard facial oedema and difficulty in opening his eyes. The rehabilitation intervention and manual lymphatic drainage improved the oedema and its consistency, as well as the patient's vision, measured with a visual analogue scale. Facial lymphedema is an unusual entity that is difficult to diagnose. Few studies have been performed of its treatment. Manual lymphatic drainage can be useful to improve the oedema and quality of life of these patients (AU)

Eritema ab igne, un peculiar efecto secundario del ordenador portátil / Erythema ab igne, a peculiar side effect of laptops

No disponible

Urticaria acuagénica / Aquagenic urticaria

Presentamos el caso de una mujer de 30 años con urticaria acuagénica; también su madre presenta el mismo diagnóstico. La urticaria acuagénica es una forma rara de urticaria física que cursa con habones que afectan generalmente la parte superior del cuerpo. Es importante hacer diagnóstico diferencial con otros tipos de urticaria. La etiopatogenia no está clara. Los antihistamínicos mejoran la clínica. (AU)

The present is the case of a 30 year-old woman with aquagenic urticaria; her mother has the same diagnosis. Aquagenic urticaria is a rare form of physical urticaria which causes wheals that usually affect the upper body. Differential diagnosis with other types of urticaria is important. Etiopathogenesis is not well known. Treatment with antihistamines improves clinical attention (AU)

Aquagenic urticaria: report of a case in an adolescent girl

No disponible

Prueba de la tuberculina en paciente con psoriasis / Tuberculin skin test in a patient with psoriasis

No disponible

Acute rheumatic fever and streptococci: the quintessential pathogenic trigger of autoimmunity.

Acute rheumatic fever (ARF) is a non-suppurative complication of pharyngeal infection with group A streptococcus. Signs and symptoms of ARF develop 2 to 3 weeks following pharyngitis and include arthritis, carditis, chorea, subcutaneous nodules, and erythema marginatum. In developing areas of the world, ARF and rheumatic heart disease are estimated to affect nearly 20 million people and remain leading causes of cardiovascular death during the first five decades of life. ARF still represents one of the quintessential examples of a pathogenic trigger culminating in autoimmune manifestations. In this review, we will focus on the pathogenesis and etiology of ARF and its complications, along with diagnostic and treatment approaches to both ameliorate and prevent long-term sequelae of this potentially debilitating disease.

Necrolytic acral erythema.

Necrolytic acral erythema is a rare, cutaneous manifestation of hepatitis C virus infection that is characterized by erythematous, violaceous or dusky papules, blisters, and/or erosions in the early stages and by well-demarcated, hyperkeratotic, targetoid plaques with a peripheral rim of macular erythema, secondary lichenification and hyperpigmentation, and overlying fine micaceous or necrotic-appearing scale in the later stages. Because most topical modalities prove ineffective, treatment of the underlying viral infection or therapeutic zinc supplementation are required for clinical improvement.

A rare case of Meleney’s Ulcer after partial chemical matricectomy

Antecedentes. La úlcera de Meleney es una infección poco frecuente, pero potencialmente grave que ocurre a menudo en el postoperatorio. Este tipo de úlcera no ha sido anteriormente descrita en el pie tras la realización de una matricectomía parcial con fenol. Caso Clínico. Una paciente fue intervenida mediante fenolización parcial de la matriz ungueal medial del dedo gordo del pie, y transcurridos 2 meses tuvo una recidiva de la deformidad ungueal que causó las úlceras de Meleney. Resultados. Las úlceras se mantuvieron sin cicatrizar aún pautando un régimen de tratamiento con antibióticos, por lo que se requirió de una nueva intervención quirúrgica para eliminar completamente la infección. Conclusión. Este caso presenta una úlcera de Meleney destacando una presentación inicial aparentemente benigna de la fascitis necrotizante en el hallux tras la realización de una matricectomía química parcial mediante abordaje quirúrgico utilizando fenol(AU)

Background. Meleney’s ulcer is a rare, but potentially deadly infection that often occurs in post-surgical sites. This type of ulcer has not previously been reported in the toenail after phenol matricectomy. Patient Case. A female patient underwent partial phenolization of the medial nail matrix of the hallux, but after 2 months had a recurrent spicula that caused Meleney’s ulcers. Results. The ulcers remained after treatment with antibiotics, and further surgery was required to fully clear the infection. Conclusion. This case and review of Meleney’s ulcer highlights the deceptively benign initial presentation of necrotizing fasciitis at the hallux after partial chemical matricectomy surgery using a phenol-based approach(AU)

Eritema anular centrífugo con respuesta a radiación ultravioleta natural / No disponible

No disponible

Lesiones anulares en neonato tras fototerapia / Annular Lesions Following Phototherapy in a Newborn Infant

No disponible

No disponible

Psoriasis en la infancia / Psoriasis in childhood

La psoriasis es una enfermedad crónica inflamatoria de la piel que afecta a un 2-3% de la población general. Aproximadamente, en uno de cada tres pacientes comienza en la edad infantil, y supone el 4% de todas las enfermedades de la piel del niño. La cara y las zonas de los pliegues se ven afectadas con frecuencia, y además son áreas especialmente sensibles a los efectos adversos de los corticoides tópicos. Los inhibidores de la calcineurina tópicos suponen una opción eficaz y segura en el tratamiento de la psoriasis invertida en niños(AU)

Psoriasis is a chronic inflammatory skin disorder that affects 2% to 3% of the population. Approximately one-third of the patients note its onset during childhood, and it accounts for 4%of the cutaneous disorders in children. The face and intertriginous areas are often involved, and they are particularly sensitive to the adverse effects of steroid use. Topical calcineurin inhibitors are an effective and safe option for the treatment of inverse psoriasis in children(AU)

[Which patient is a candidate for treatment with efalizumab and why?]. / Cuál es el paciente candidato a tratamiento con efalizumab y por qué?

With the coming of the biological therapies, long-term maintained control of psoriasis is becoming a reality and means a significant improvement in the quality of life in some patients with persistent clearing of the disease. This result was difficult to obtain previously. Efalizumab, a recombinant IgG1 anti-CD11a antibody approved for the treatment of psoriasis in moderate-to-severe chronic plaques, has an excellent safety profile and its therapeutic results in the clinical practice have surpassed the expectations based on the clinical trials. At 12 weeks of treatment (when its efficacy should be evaluated), a PASI 75 response can be expected in 35 to 40% of the patients and a PASI 50 response in two thirds of them. This degree of improvement may be maintained and may even increase in 80% of the patients, making it possible to achieve an almost complete clearing in more than 40% of the patients who continue the treatment over several years. Localized, transitory exacerbations may appear, especially in the beginning of the treatment, but these can generally be managed in combination with another treatment. There may also be generalized inflammatory outbreaks, especially in patients with scarce or null response, who require treatment with a rapid effect systemic drug at the onset. This is because they may be a prelude to the development of rebounds, that may acquire an erythrodermic or pustular morphology or be accompanied by arthritis, and which tend to appear after the sudden withdrawal of the drug. An adequate selection of the patients may maximize the possibilities of success. Patients without arthritis and with stable, extensive and non-inflammatory forms of the disease tend to be the best candidates. Special attention should be given to the administration of systemic agents in transition regimes when efalizumab is introduced or withdrawn. The clinical criteria is fundamental to optimize the therapeutic results with efalizumab, that may be an attractive challenge but may also be an especially satisfactory therapeutic option when long-term control is the disease is proposed.

Pitiriasis liquenoide y varioliforme aguda (enfermedad de Mucha-Haberman) / Pityriasis lichenoides et varioliformis acuta (Mucha-Habermann disease)

No disponible